导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 33.19% | 98/4773 |
| 近一周 | 0.82% | 564/5465 |
| 近一月 | -2.31% | 1574/5421 |
| 近一季 | -16.79% | 4523/5231 |
| 近半年 | 26.29% | 105/4920 |
| 近一年 | 45.55% | 99/4394 |
| 近两年 | 222.97% | 65/2954 |
| 近三年 | 207.57% | 13/2253 |
| 成立以来 | 136.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.81% 1978/4961 |
73.87% 225/5312 |
- - |
- - |
| 2025 | 82.18% 95/4813 |
0.82% 1764/3635 |
4.65% 722/4076 |
64.51% 47/4524 |
4.97% 466/4813 |
| 2024 | 26.01% 235/3463 |
0.21% 1020/2808 |
7.04% 108/3014 |
10.89% 2581/3129 |
5.94% 568/3463 |
| 2023 | 18.04% 26/2656 |
24.76% 100/2280 |
4.97% 78/2385 |
-9.26% 1794/2515 |
-0.67% 240/2655 |
| 2022 | -34.17% 1713/2207 |
-26.47% 1792/1919 |
4.34% 1024/2016 |
-17.59% 1620/2113 |
4.12% 583/2208 |
| 2021 | 11.08% 407/1822 |
-11.74% 1141/1255 |
19.32% 162/1330 |
-10.01% 1204/1466 |
17.20% 45/1822 |
| 2020 | - - |
- - |
- - |
-1.54% 1069/1164 |
0.84% 1048/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 博时中证5G产业50ETF VS. 长安沪深300非周期A(740101) |